false
0001314052
0001314052
2025-11-14
2025-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November
14, 2025
ANAVEX
LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
| Nevada |
001-37606 |
98-0608404 |
| (State or other jurisdiction |
(Commission |
(IRS Employer |
| of incorporation) |
File Number) |
Identification No.) |
630 5th Avenue
20th Floor
New York, NY 10111
(Address of principal executive offices) (Zip Code)
1-844-689-3939
(Registrant’s telephone number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class |
|
Trading Symbol |
|
Name of Each Exchange on Which Registered |
| Common Stock, par value $0.001 per share |
|
AVXL |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On November 14, 2025, Anavex Life Sciences Corp. (the
“Company”) issued a press release announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA) has rendered a negative trend vote following an oral explanation of the Company’s Marketing Authorization
Application (MAA) for blarcamesine.
The Company intends to request a re-examination of
the CHMP opinion upon its formal adoption, including providing relevant biomarker data, based on feedback and continued guidance from
the CHMP, EMA and the Alzheimer’s disease community.
A copy of the press release is furnished as Exhibit
99.1 and is incorporated herein by reference, including the cautionary statement on forward-looking statements included in the press release.
Item
9.01 Financial Statements and Exhibits.
| EXHIBIT
NO. |
|
DESCRIPTION |
|
LOCATION |
| 99.1 |
|
Press release dated November 14, 2025 |
|
Filed
herewith |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
|
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| ANAVEX LIFE SCIENCES CORP. |
| |
| By: |
/s/ Christopher Missling |
|
| |
Name: Christopher Missling, PhD
|
|
| |
Title: Chief Executive Officer |
|
Date: November 14, 2025
